TY  - JOUR
AU  - Sponholz, Stefan
AU  - Koch, Agnes
AU  - Mese, Mesut
AU  - Becker, Silvan
AU  - Sebastian, Martin
AU  - Fischer, Sebastian
AU  - Trainer, Stephan
AU  - Schreiner, Waldemar
TI  - Lung Cancer Resection after Immunochemotherapy Versus Chemotherapy in Oligometastatic Nonsmall Cell Lung Cancer
JO  - The thoracic and cardiovascular surgeon
VL  - 71
IS  - 8
SN  - 0371-7364
CY  - Stuttgart
PB  - Thieme
M1  - DKFZ-2023-00782
SP  - 656-663
PY  - 2023
N1  - 2023 Dec;71(8):656-663
AB  - Background: Neoadjuvant immunochemotherapy is currently being tested in pivotal trials for stage I to III nonsmall cell lung cancer (NSCLC). The impact of immunochemotherapy in patients with oligometastatic disease (OMD) remains undefined. This study aimed to compare the outcomes of radical treatment after the neoadjuvant course of immunochemotherapy versus chemotherapy.Methods: We retrospectively analyzed patients with OMD who were treated with immunochemotherapy or chemotherapy combined with local ablation of metastases and radical primary tumor resection between 2017 and 2021. Group A included eight patients with immunochemotherapy; Group B included seven patients with chemotherapy. Descriptive statistical analysis included the characteristics of the patients, tumors, and outcomes.Results: There was no difference in postoperative morbidity rates between the groups (p = 0.626). The 30-day mortality in both groups was 0
LB  - PUB:(DE-HGF)16
C6  - pmid:36746400
DO  - DOI:10.1055/a-2028-7955
UR  - https://inrepo02.dkfz.de/record/275472
ER  -